1.285
Schlusskurs vom Vortag:
$1.27
Offen:
$1.27
24-Stunden-Volumen:
2.08M
Relative Volume:
0.86
Marktkapitalisierung:
$970.29M
Einnahmen:
$581.12M
Nettoeinkommen (Verlust:
$-212.92M
KGV:
-4.6932
EPS:
-0.2738
Netto-Cashflow:
$-174.22M
1W Leistung:
+11.74%
1M Leistung:
+4.47%
6M Leistung:
-4.10%
1J Leistung:
+1.98%
Opko Health Inc Stock (OPK) Company Profile
Firmenname
Opko Health Inc
Sektor
Branche
Telefon
305-575-4181
Adresse
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
OPK
Opko Health Inc
|
1.285 | 958.97M | 581.12M | -212.92M | -174.22M | -0.2738 |
|
TMO
Thermo Fisher Scientific Inc
|
448.35 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
172.85 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
557.99 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
|
WAT
Waters Corp
|
339.37 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
|
A
Agilent Technologies Inc
|
115.50 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | JP Morgan | Neutral |
| 2025-10-31 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-25 | Eingeleitet | JP Morgan | Neutral |
| 2023-06-29 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-24 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-11-25 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-03-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-06-21 | Bestätigt | Standpoint Research | Buy |
| 2016-06-03 | Eingeleitet | Standpoint Research | Buy |
| 2016-03-31 | Bestätigt | Barrington Research | Outperform |
| 2015-10-16 | Eingeleitet | JP Morgan | Overweight |
| 2015-09-11 | Herabstufung | Jefferies | Buy → Hold |
| 2015-03-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2014-05-12 | Bestätigt | Oppenheimer | Outperform |
| 2014-03-14 | Eingeleitet | Oppenheimer | Outperform |
| 2013-11-13 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-05-30 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-10-22 | Eingeleitet | Barrington Research | Outperform |
| 2011-12-01 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-07-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Opko Health Inc Aktie (OPK) Neueste Nachrichten
Here's why you should retain OPK stock in your portfolio for now - MSN
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook - AD HOC NEWS
OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus - AD HOC NEWS
Opko Health, Inc.Common Stock (NQ: OPK - FinancialContent
OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS
ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK
OPKO Health’s ModeX Therapeutics Will Present Data - GlobeNewswire
Spotlight On Promising Penny Stocks For May 2026 - simplywall.st
OPK.O| Stock Price & Latest News - Reuters
Here's why you should hold OPK stock in your portfolio for now - msn.com
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
MSN Money - MSN
OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill
OPKO Health, Inc. (NASDAQ:OPK) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat
OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com
OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK
[ARS] OPKO HEALTH, INC. SEC Filing - Stock Titan
Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan
OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa
OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat
Order lab tests online or at home: BioReference opens new platform - Stock Titan
BioReference Launches BioReference Direct, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - Moomoo
OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com
OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo
OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat
This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia
OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat
H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com
OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... By GuruFocus - Investing.com Canada
OPKO Health Q1 2026 Earnings Call Transcript - MarketBeat
OPKO Health Q1 Earnings Call Highlights - MarketBeat
OPK: Clinical pipeline advances and operational improvements drive improved Q1 2026 results - TradingView
Finanzdaten der Opko Health Inc-Aktie (OPK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Opko Health Inc-Aktie (OPK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):